{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:33:41Z","timestamp":1787672021085,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40266-018-0598-3","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T02:41:26Z","timestamp":1539139286000},"page":"1065-1078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evidence-Based Management of Diabetes in Older Adults"],"prefix":"10.1007","volume":"35","author":[{"given":"Arshag D.","family":"Mooradian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"598_CR1","unstructured":"National Center for Chronic Disease Prevention and Health Promotion; Division of Diabetes Translation. National Diabetes Statistics Report, 2017. http:\/\/www.diabetes.org\/assets\/pdfs\/basics\/cdc-statistics-report-2017.pdf. Accessed 9 Nov 2018."},{"issue":"Suppl 1","key":"598_CR2","first-page":"47","volume":"81","author":"G Paolisso","year":"2010","unstructured":"Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed. 2010;81(Suppl 1):47\u201353.","journal-title":"Acta Biomed"},{"key":"598_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00002512-199303020-00004","volume":"3","author":"AD Mooradian","year":"1993","unstructured":"Mooradian AD. Mechanisms of age-related endocrine alterations. Part II. Drugs Aging. 1993;3:131\u201346.","journal-title":"Drugs Aging"},{"key":"598_CR4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0026-0495(95)90161-2","volume":"44","author":"SJ Giddings","year":"1995","unstructured":"Giddings SJ, Carnaghi LR, Mooradian AD. Age-related changes in pancreatic islet cell gene expression. Metabolism. 1995;44:320\u20134.","journal-title":"Metabolism"},{"issue":"5 supplement","key":"598_CR5","first-page":"S265","volume":"51","author":"AF Brown","year":"2003","unstructured":"Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus, California Healthcare Foundation\/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. J Am Geriatr Soc. 2003;51(5 supplement):S265\u201380.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR6","first-page":"18","volume":"59","author":"DE Olson","year":"2004","unstructured":"Olson DE, Norris SL. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics. 2004;59:18\u201324.","journal-title":"Geriatrics"},{"issue":"Suppl 3","key":"598_CR7","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1262-3636(11)70962-4","volume":"37","author":"AJ Sinclair","year":"2011","unstructured":"Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Ma\u00f1as L, European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27\u201338.","journal-title":"Diabetes Metab"},{"key":"598_CR8","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/jama.295.16.1935","volume":"295","author":"SC Durso","year":"2006","unstructured":"Durso SC. Using clinical guidelines for older adult patients with diabetes mellitus and complex health status. JAMA. 2006;295:1935\u201340.","journal-title":"JAMA"},{"key":"598_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/gerona\/59.2.M148","volume":"59","author":"SC Maty","year":"2004","unstructured":"Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci. 2004;59:148\u201353.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"598_CR10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/gerona\/60.9.1206","volume":"60","author":"LA Wray","year":"2005","unstructured":"Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2005;60:1206\u201311.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"598_CR11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/gerona\/60.12.1539","volume":"60","author":"S Volpato","year":"2005","unstructured":"Volpato S, Leveille SG, Blaum C, Fried LP, Guralnik JM. Risk factors for falls in older disabled women with diabetes: the women\u2019s health and aging study. J Gerontol A Biol Sci Med Sci. 2005;60:1539\u201345.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"598_CR12","first-page":"170","volume":"2","author":"AD Mooradian","year":"1989","unstructured":"Mooradian AD. Psychosocial aspects of diabetes in the elderly. Diabetes Spectr. 1989;2:170\u20132.","journal-title":"Diabetes Spectr"},{"key":"598_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jamda.2009.02.010","volume":"10","author":"SM Feldman","year":"2009","unstructured":"Feldman SM, Rosen R, De Stasio J. Status of diabetes management in the nursing home setting in 2008: a retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Dir Assoc. 2009;10:354\u201360.","journal-title":"J Am Med Dir Assoc"},{"key":"598_CR14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/B978-012369391-4\/50057-6","volume-title":"Handbook of models for human aging","author":"AD Mooradian","year":"2006","unstructured":"Mooradian AD. Diabetes as a model of premature aging. In: Cohn M, editor. Handbook of models for human aging. Burlington, MA: Elsevier Academic Press; 2006. p. 687\u201395."},{"key":"598_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1532-5415.1988.tb04269.x","volume":"36","author":"AD Mooradian","year":"1988","unstructured":"Mooradian AD. Tissue specificity of premature aging in diabetes mellitus: the role of cellular replicative capacity. J Am Geriatr Soc. 1988;36:831\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1994.tb04941.x","volume":"42","author":"N Morisaki","year":"1994","unstructured":"Morisaki N, Watanabe S, Kobayashi J, Kanzaki T, Takahashi K, Yokote K, Tezuka M, Tashiro J, Inadera H, Saito Y, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994;42:142\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ageing\/afl019","volume":"35","author":"KN Barnett","year":"2006","unstructured":"Barnett KN, McMurdo ME, Ogston SA, Morris AD, Evans JM. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing. 2006;35:463\u20138.","journal-title":"Age Ageing"},{"key":"598_CR18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbj\u00f6rnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720\u201332.","journal-title":"N Engl J Med"},{"key":"598_CR19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00125-018-4544-z","volume":"61","author":"L Huo","year":"2018","unstructured":"Huo L, Magliano DJ, Ranci\u00e8re F, Harding JL, Nanayakkara N, Shaw JE, Carstensen B. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997\u20132011. Diabetologia. 2018;61:1055\u201363.","journal-title":"Diabetologia"},{"key":"598_CR20","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00125-014-3369-7","volume":"57","author":"S Zoungas","year":"2014","unstructured":"Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, Williams B, Chalmers J, ADVANCE Collaborative group. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465\u201374.","journal-title":"Diabetologia."},{"key":"598_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393\u2013403.","journal-title":"N Engl J Med"},{"key":"598_CR22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/oxfordjournals.aje.a113625","volume":"118","author":"MC Leske","year":"1983","unstructured":"Leske MC, Sperduto RD. The epidemiology of senile cataracts: a review. Am J Epidemiol. 1983;118:152\u201365.","journal-title":"Am J Epidemiol"},{"key":"598_CR23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/oxfordjournals.aje.a113626","volume":"118","author":"MC Leske","year":"1983","unstructured":"Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166\u201391.","journal-title":"Am J Epidemiol"},{"key":"598_CR24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0002-9343(87)90767-4","volume":"83","author":"JE Morley","year":"1987","unstructured":"Morley JE, Mooradian AD, Rosenthal MH, Kaiser FE. Diabetes mellitus in the elderly: is it different? Am J Med. 1987;83:533\u201344.","journal-title":"Am J Med"},{"key":"598_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1532-5415.1991.tb01644.x","volume":"39","author":"SL Evans","year":"1991","unstructured":"Evans SL, Nixon BP, Lee I, Yee D, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc. 1991;39:241\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.mjt.0000132252.80403.c9","volume":"13","author":"AD Mooradian","year":"2006","unstructured":"Mooradian AD, Korenman SG. Management of the cardinal features of andropause. Am J Ther. 2006;13:145\u201360.","journal-title":"Am J Ther"},{"key":"598_CR27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0749-0690(18)30581-0","volume":"6","author":"TJ Wachtel","year":"1990","unstructured":"Wachtel TJ. The diabetic-hyperosmolar state. Clin Geriatr Med. 1990;6:797\u2013806.","journal-title":"Clin Geriatr Med"},{"key":"598_CR28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/dc07-1152","volume":"31","author":"AV Schwartz","year":"2008","unstructured":"Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW, Faulkner KA, Harris TB, Health, Aging, and Body Composition Study. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391\u20136.","journal-title":"Diabetes Care"},{"key":"598_CR29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2389.2003.51256.x","volume":"51","author":"CS Blaum","year":"2003","unstructured":"Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc. 2003;51:745\u201353.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1532-5415.2009.02196.x","volume":"57","author":"CS Blaum","year":"2009","unstructured":"Blaum CS, Xue QL, Tian J, Semba RD, Fried LP, Walston J. Is hyperglycemia associated with frailty status in older women? J Am Geriatr Soc. 2009;57:840\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR31","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/archinte.1988.00380110035007","volume":"148","author":"AD Mooradian","year":"1988","unstructured":"Mooradian AD, Perryman K, Fitten J, Kavonian G, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients: behavioral and electrophysiological studies. Arch Int Med. 1988;148:2369\u201372.","journal-title":"Arch Int Med"},{"key":"598_CR32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1210\/edrv-9-3-346","volume":"9","author":"AD Mooradian","year":"1988","unstructured":"Mooradian AD. Diabetic complications of the central nervous system. Endocr Rev. 1988;9:346\u201356.","journal-title":"Endocr Rev"},{"key":"598_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF02435039","volume":"16","author":"AD Mooradian","year":"1993","unstructured":"Mooradian AD, Siverly FD. Qualitative differences in the visual retention test performance of older non-insulin dependent diabetic patients. Age. 1993;16:67\u20139.","journal-title":"Age"},{"key":"598_CR34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765\u201372.","journal-title":"Lancet"},{"key":"598_CR35","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"598_CR36","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55\u201364.","journal-title":"Diabetes Care"},{"key":"598_CR37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2011.05.020","volume":"58","author":"SC Chung","year":"2011","unstructured":"Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM, BARI 2D Study Group. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol. 2011;58:810\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"598_CR38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2017.03.048","volume":"241","author":"AA Damluji","year":"2017","unstructured":"Damluji AA, Cohen ER, Moscucci M, Myerburg RJ, Cohen MG, Brooks MM, Rich MW, Forman DE. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. Int J Cardiol. 2017;241:35\u201340.","journal-title":"Int J Cardiol"},{"key":"598_CR39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MJT.0b013e3181ff7e37","volume":"19","author":"AD Mooradian","year":"2012","unstructured":"Mooradian AD, Chehade JM. Diabetes mellitus in older adults. Am J Ther. 2012;19:145\u201359.","journal-title":"Am J Ther"},{"issue":"suppl 5A","key":"598_CR40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0002-9343(86)90538-3","volume":"8","author":"SM Holvey","year":"1986","unstructured":"Holvey SM. Psychosocial aspects in the care of elderly diabetic patients. Am J Med. 1986;8(suppl 5A):61\u20133.","journal-title":"Am J Med"},{"key":"598_CR41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0197-4580(94)90098-1","volume":"15","author":"AD Mooradian","year":"1994","unstructured":"Mooradian AD. Behavioral effects if noninsulin-dependent diabetes mellitus in the elderly. Neurobiol Aging. 1994;15:565\u20137.","journal-title":"Neurobiol Aging"},{"key":"598_CR42","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/archpsyc.61.10.1042","volume":"61","author":"WJ Katon","year":"2004","unstructured":"Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"598_CR43","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 2. Diagnosis and classification of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13\u201327.","journal-title":"Diabetes Care"},{"key":"598_CR44","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-152-12-201006150-00004","volume":"152","author":"DC Ziemer","year":"2010","unstructured":"Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, Narayan KM, Koch DD, Phillips LS. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770\u20137.","journal-title":"Ann Intern Med"},{"key":"598_CR45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0006-8993(91)90926-M","volume":"551","author":"AD Mooradian","year":"1991","unstructured":"Mooradian AD, Morin A, Clip L, Haspel H. Glucose transport is reduced in the blood\u2013brain barrier of aged rats. Brain Res. 1991;551:145\u20139.","journal-title":"Brain Res"},{"key":"598_CR46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF00965565","volume":"16","author":"AD Mooradian","year":"1991","unstructured":"Mooradian AD, Scarpace PJ. \u03b2-Adrenergic receptor activity of cerebral microvessels is reduced in aged rats. Neurochem Res. 1991;16:447\u201351.","journal-title":"Neurochem Res"},{"key":"598_CR47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0165-0173(97)00003-9","volume":"23","author":"AD Mooradian","year":"1997","unstructured":"Mooradian AD. Central nervous system complications of diabetes mellitus. A perspective from the blood\u2013brain barrier. Brain Res Rev. 1997;23:210\u20138.","journal-title":"Brain Res Rev"},{"key":"598_CR48","first-page":"322","volume":"4","author":"AD Mooradian","year":"1997","unstructured":"Mooradian AD. Pathophysiology of central nervous system disorders in diabetes. Clin Neurosci. 1997;4:322\u20136.","journal-title":"Clin Neurosci"},{"key":"598_CR49","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.162.20.2269","volume":"162","author":"JL Wolff","year":"2002","unstructured":"Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269\u201376.","journal-title":"Arch Intern Med"},{"key":"598_CR50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/diacare.26.5.1344","volume":"26","author":"MR Niefeld","year":"2003","unstructured":"Niefeld MR, Braunstein JB, Wu AW, Saudek CD, Weller WE, Anderson GF. Hospitalization among elderly medicare beneficiaries with type 2 diabetes. Diabetes Care. 2003;26:1344\u20139.","journal-title":"Diabetes Care"},{"key":"598_CR51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1377\/hlthaff.20.6.233","volume":"20","author":"BG Druss","year":"2001","unstructured":"Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233\u201341.","journal-title":"Health Aff (Millwood)"},{"key":"598_CR52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2337\/diacare.29.03.06.dc05-2078","volume":"29","author":"JD Piette","year":"2006","unstructured":"Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725\u201331.","journal-title":"Diabetes Care"},{"key":"598_CR53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0749-0690(18)30587-1","volume":"6","author":"RL Reed","year":"1990","unstructured":"Reed RL, Mooradian AD. Nutritional status and dietary management of elderly diabetic patients. Clin Geriatr Med. 1990;6:883\u2013902.","journal-title":"Clin Geriatr Med"},{"key":"598_CR54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1532-5415.1988.tb02376.x","volume":"36","author":"AD Mooradian","year":"1988","unstructured":"Mooradian AD, Osterweil D, Petrasek D, Morley JE. Diabetes mellitus in the elderly nursing home patients: a survey of clinical characteristics and management. J Am Geriatr Soc. 1988;36:391\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02432386","volume":"13","author":"AD Mooradian","year":"1990","unstructured":"Mooradian AD, Kalis J, Nugent CA. The nutritional status of ambulatory elderly type II diabetic patients. Age. 1990;13:87\u20139.","journal-title":"Age"},{"key":"598_CR56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00002512-199711060-00003","volume":"11","author":"JE Thurman","year":"1997","unstructured":"Thurman JE. Mooradian AD Vitamin supplementation therapy in the elderly. Drugs Aging. 1997;11:433\u201349.","journal-title":"Drugs Aging"},{"key":"598_CR57","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/gerona\/60.11.1425","volume":"60","author":"EF Binder","year":"2005","unstructured":"Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB, Holloszy JO. Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol A Biol Sci Med Sci. 2005;60:1425\u201331.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"598_CR58","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199406233302501","volume":"330","author":"MA Fiatarone","year":"1994","unstructured":"Fiatarone MA, O\u2019Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769\u201375.","journal-title":"N Engl J Med"},{"key":"598_CR59","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003495-199651060-00002","volume":"6","author":"AD Mooradian","year":"1996","unstructured":"Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs. 1996;6:931\u201341.","journal-title":"Drugs"},{"key":"598_CR60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003495-200060010-00006","volume":"60","author":"JM Chehade","year":"2000","unstructured":"Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95\u2013113.","journal-title":"Drugs"},{"key":"598_CR61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0753-3322(03)00052-0","volume":"57","author":"R Oiknine","year":"2003","unstructured":"Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 2003;57:231\u20139.","journal-title":"Biomed Pharmacother"},{"key":"598_CR62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/9780470744093.ch17","volume-title":"Diabetes in old age","author":"J Chehade","year":"2009","unstructured":"Chehade J, Mooradian AD. Drug therapy: current and emerging agents for hyperglycemia. In: Sinclair AJ, editor. Diabetes in old age. 3rd ed. Hoboken: Wiley; 2009. p. 245\u201364.","edition":"3"},{"key":"598_CR63","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"598_CR64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319\u201328.","journal-title":"N Engl J Med"},{"key":"598_CR65","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723\u201332.","journal-title":"N Engl J Med"},{"key":"598_CR66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003495-200565030-00003","volume":"65","author":"R Oiknine","year":"2005","unstructured":"Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. Drugs. 2005;65:325\u201340.","journal-title":"Drugs"},{"key":"598_CR67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/0003-4819-145-2-200607180-00010","volume":"145","author":"AD Mooradian","year":"2006","unstructured":"Mooradian AD, Bernbaum M, Albert SG. A narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125\u201334.","journal-title":"Ann Intern Med"},{"key":"598_CR68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1532-5415.2007.01043.x","volume":"55","author":"HU Janka","year":"2007","unstructured":"Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR69","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2337\/diacare.28.7.1568","volume":"28","author":"WH Herman","year":"2005","unstructured":"Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568\u201373.","journal-title":"Diabetes Care"},{"key":"598_CR70","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1353\/pbm.2004.0071","volume":"47","author":"TB Schwartz","year":"2004","unstructured":"Schwartz TB, Meinert CL. The UGDP controversy: 34\u00a0years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47:564\u201374.","journal-title":"Perspect Biol Med"},{"key":"598_CR71","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"598_CR72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicenter trial. Lancet Diabetes Endocrinol. 2017;5:887\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"598_CR73","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/archinte.1997.00440360095010","volume":"157","author":"RI Shorr","year":"1997","unstructured":"Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681\u20136.","journal-title":"Arch Intern Med"},{"key":"598_CR74","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"598_CR75","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet Lond Engl. 2009;373:2125\u201335.","journal-title":"Lancet Lond Engl"},{"key":"598_CR76","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"598_CR77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"598_CR78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"J-L Chiasson","year":"2003","unstructured":"Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u201394.","journal-title":"JAMA"},{"key":"598_CR79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","volume":"25","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10\u20136.","journal-title":"Eur Heart J"},{"key":"598_CR80","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"598_CR81","first-page":"1515","volume":"83","author":"PS Johnston","year":"1998","unstructured":"Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"598_CR82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8227(01)00359-X","volume":"56","author":"MJ Deleon","year":"2002","unstructured":"Deleon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101\u20136.","journal-title":"Diabetes Res Clin Pract"},{"key":"598_CR83","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0002-9629(15)40761-X","volume":"319","author":"AD Mooradian","year":"2000","unstructured":"Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with Type 2 diabetes. Am J Med Sci. 2000;319:334\u20137.","journal-title":"Am J Med Sci"},{"key":"598_CR84","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579\u201388.","journal-title":"Circulation"},{"key":"598_CR85","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"598_CR86","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"598_CR87","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jamda.2017.11.002","volume":"19","author":"GE Umpierrez","year":"2018","unstructured":"Umpierrez GE, Cardona S, Chachkhiani D, et al. A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC Trial. J Am Med Dir Assoc. 2018;19:399\u2013404.","journal-title":"J Am Med Dir Assoc"},{"key":"598_CR88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"598_CR89","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"598_CR90","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"598_CR91","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"598_CR92","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"598_CR93","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"598_CR94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","volume":"71","author":"MB Mortensen","year":"2018","unstructured":"Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"598_CR95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet"},{"key":"598_CR96","doi-asserted-by":"crossref","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998\u20133007.","DOI":"10.1001\/jama.288.23.2998"},{"key":"598_CR97","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp RH, d\u2019Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478\u201385.","journal-title":"Diabetes Care"},{"issue":"9364","key":"598_CR98","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet"},{"key":"598_CR99","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376:1670\u201381.","journal-title":"Lancet Lond Engl"},{"key":"598_CR100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1\u201345.","journal-title":"Circulation"},{"key":"598_CR101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"HPS Heart Protection Study Collaborative Group","year":"2002","unstructured":"HPS Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Lond Engl. 2002;360:7\u201322.","journal-title":"Lancet Lond Engl"},{"key":"598_CR102","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"598_CR103","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"598_CR104","unstructured":"http:\/\/www.acc.org\/latest-in-cardiology\/articles\/2018\/03\/05\/15\/53\/sat-9am-odyssey-outcomes-cv-outcomes-with-alirocumab-after-acs-acc-2018. Accessed 2 Jun 2018."},{"key":"598_CR105","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"key":"598_CR106","first-page":"150","volume":"5","author":"AD Mooradian","year":"2009","unstructured":"Mooradian AD. Dyslipidemia of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150\u20139.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"598_CR107","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control (SPRINT). N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"598_CR108","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. The ACCORD study group. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"598_CR109","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922\u201344.","journal-title":"J Hypertens"},{"key":"598_CR110","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","volume":"123","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and Bayesian random-effects metaanalyses of randomized trials. Circulation. 2011;123:2799\u2013810.","journal-title":"Circulation"},{"key":"598_CR111","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet Lond Engl. 2016;387:957\u201367.","journal-title":"Lancet Lond Engl"},{"key":"598_CR112","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WSD, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. JACC. 2018;71:e127\u2013248.","journal-title":"JACC"},{"key":"598_CR113","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"598_CR114","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-018-0887-5","volume":"78","author":"WS Aronow","year":"2018","unstructured":"Aronow WS, Frishman WH. Contemporary drug treatment of hypertension: focus on recent guidelines. Drugs. 2018;78:567\u201376.","journal-title":"Drugs."},{"key":"598_CR115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/00325481.2018.1433434","volume":"130","author":"SG Chrysant","year":"2018","unstructured":"Chrysant SG. Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgrad Med. 2018;130:159\u201365.","journal-title":"Postgrad Med"},{"key":"598_CR116","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","volume":"134","author":"D Capodanno","year":"2016","unstructured":"Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579\u201394.","journal-title":"Circulation"},{"key":"598_CR117","doi-asserted-by":"publisher","unstructured":"ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/nejmoa1804988 (Epub ahead of print).","DOI":"10.1056\/nejmoa1804988"},{"issue":"Suppl 1","key":"598_CR118","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S86\u2013104.","journal-title":"Diabetes Care"},{"key":"598_CR119","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. An update of the 2011 ACC\/AHA\/SCAI PCI guideline, 2011 ACC\/AHA CABG guideline, 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS SIHD guideline, 2013 ACC\/AHA STEMI guideline, 2014 ACC\/AHA NSTE-ACS guideline, and 2014 ACC\/AHA Perioperative guideline. J Am Coll Cardiol. 2016;68:1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"key":"598_CR120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1532-5415.1994.tb06541.x","volume":"42","author":"M Bernbaum","year":"1994","unstructured":"Bernbaum M, Albert SG, McGinnis J, Brusca S, Mooradian AD. The reliability of self blood glucose monitoring in elderly diabetic patients. J Am Geriatr Soc. 1994;42:779\u201381.","journal-title":"J Am Geriatr Soc"},{"key":"598_CR121","first-page":"005060","volume":"1","author":"UL Malanda","year":"2012","unstructured":"Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:005060.","journal-title":"Cochrane Database Syst Rev"},{"key":"598_CR122","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jdiacomp.2018.05.005","volume":"32","author":"K Mattishent","year":"2018","unstructured":"Mattishent K, Loke YK. Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people\u2014systematic review. J Diabetes Complicat. 2018;32:805\u201312.","journal-title":"J Diabetes Complicat"},{"key":"598_CR123","first-page":"100","volume":"6","author":"RL Reed","year":"1998","unstructured":"Reed RL, Mooradian AD. Management of diabetes mellitus in the nursing home. Ann Long Term Care. 1998;6:100\u20137.","journal-title":"Ann Long Term Care"},{"key":"598_CR124","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40265-017-0857-3","volume":"78","author":"DR Saxon","year":"2018","unstructured":"Saxon DR, Rasouli N, Eckell RH. Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents. Drugs. 2018;78:203\u201314.","journal-title":"Drugs"},{"key":"598_CR125","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1463-1326.2010.01225.x","volume":"12","author":"RE Aubert","year":"2010","unstructured":"Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"598_CR126","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1345\/aph.1M676","volume":"44","author":"SL Anderson","year":"2010","unstructured":"Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44:904\u20139.","journal-title":"Ann Pharmacother"},{"key":"598_CR127","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc10-0482","volume":"33","author":"R Garg","year":"2010","unstructured":"Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349\u201354.","journal-title":"Diabetes Care"},{"key":"598_CR128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2337\/dc17-1525","volume":"41","author":"S Kohler","year":"2018","unstructured":"Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care. 2018;41:1809\u201316.","journal-title":"Diabetes Care"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-018-0598-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:05:49Z","timestamp":1744715149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-018-0598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":128,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0598-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arshag D. Mooradian has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}